Amgen and Illumina-backed genetic sequencing technology developer Oxford Nanopore is reportedly eyeing a $2.1bn private placement.

Oxford Nanopore, the UK-based genetic sequencing technology developer backed by pharmaceutical firm Amgen, is looking to raise £1.6bn ($2.1bn) in a forthcoming private placement, The Times reported yesterday. Founded in 2005, Oxford Nanopore has devised real-time DNA and RNA sequencing technology that offers biological analyses at comparatively low cost. It has potential applications in disease…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.